2026 MedTech M&A Forecast: Blockbuster Deals in Diagnostics & Structural Heart or Continued Caution?

This episode forecasts the state of medical technology mergers and acquisitions for 2026. We analyze whether the industry will see a return to large, transformative deals driven by the need to fill portfolio gaps in diagnostics, structural heart, and workflow assets, or if valuation discipline and integration risks will ensure the market remains focused on smaller, more selective acquisitions. - Will 2026 mark the return of mega-mergers in the medical device industry? - What portfolio gaps are large medtech companies trying to fill? - Why are diagnostics and structural heart technologies so attractive for acquisition? - How do high valuations and integration risks impact M&A decisions? - What role will regulatory scrutiny play in future deals? - Are smaller 'tuck-in' acquisitions a safer bet for growth? - How can companies prepare their regulatory strategy for post-merger integration? Successful M&A is just the first step; integrating a new portfolio and achieving global market access is the next challenge. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, ensuring your expanded product line meets international compliance. Our experts develop efficient regulatory strategies and use advanced AI to compile technical dossiers, streamlining submissions across 30+ markets. Whether you're a startup or a multinational enterprise navigating post-acquisition complexities, we provide the local expertise and data tools to accelerate your global growth. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools at https://pureglobal.ai.